Meeting of the Advisory Committee on Infant and Maternal Mortality, 71908-71909 [2024-19741]
Download as PDF
<![CDATA[
71908
Federal Register / Vol. 89, No. 171 / Wednesday, September 4, 2024 / Notices
website at https://www.hrsa.gov/
advisory-committees/vaccines/
index.html.
ACCV was
established by Title XXI of the Public
Health Service Act and advises the
Secretary on issues related to
implementation of the VICP. ACCV
meets four times each calendar year, or
at the discretion of the Designated
Federal Officer in consultation with the
Chair.
Nominations: HRSA is requesting
nominations for voting members to
serve as Special Government Employees
(SGEs) on ACCV to fill open positions.
The Secretary appoints ACCV members
with the expertise needed to fulfill the
duties of the Commission. The
membership requirements are set forth
in section 2119 of the Public Health
Service Act.
ACCV consists of nine voting
members appointed by the Secretary as
follows: (1) three health professionals,
who are not employees of the United
States government, and who have
expertise in the health care of children,
the epidemiology, etiology, and
prevention of childhood diseases, and
the adverse reactions associated with
vaccines, of whom at least two shall be
pediatricians; (2) three members from
the general public, of whom at least two
shall be legal representatives (parents or
guardians) of children who have
suffered a vaccine-related injury or
death; and (3) three attorneys, of whom
at least one shall be an attorney whose
specialty includes representation of
persons who have suffered a vaccinerelated injury or death, and of whom
one shall be an attorney whose specialty
includes representation of vaccine
manufacturers. In addition, the Director
of the National Institutes of Health, the
Assistant Secretary for Health, the
Director of the Centers for Disease
Control and Prevention, and the
Commissioner of the Food and Drug
Administration (or the designees of such
officials) serve as nonvoting ex officio
members.
HHS will consider nominations of all
qualified individuals to ensure the
ACCV includes the areas of subject
matter expertise noted above. As
indicated, at least two of the three
ACCV members from the general public
must be legal representatives (parents or
guardians) of children who have
suffered a vaccine-related injury or
death. To be considered for
appointment to the ACCV in that
category, there must have been a finding
(i.e., a decision) by the U.S. Court of
Federal Claims or a civil court that a
VICP-covered vaccine caused, or was
ddrumheller on DSK120RN23PROD with NOTICES1
SUPPLEMENTARY INFORMATION:
VerDate Sep<11>2014
21:26 Sep 03, 2024
Jkt 262001
presumed to have caused, the
represented child’s injury or death.
Additionally, based on a
recommendation made by ACCV, the
Secretary will consider having a health
professional with expertise in obstetrics
as one of the members from the general
public. Interested applicants may selfnominate or be nominated by another
individual or organization.
Individuals selected for appointment
to the Commission will be invited to
serve for up to 3 years. Members
appointed as SGEs receive a stipend and
reimbursement for per diem and travel
expenses incurred for attending ACCV
meetings and/or conducting other
business on behalf of ACCV, as
authorized by 5 U.S.C. 5703, for persons
employed intermittently in government
service.
The following information must be
included in the package of materials
submitted for each individual
nominated for consideration: (1) a letter
of nomination stating the name,
affiliation, and contact information for
the nominee, the basis for the
nomination (i.e., what specific
attributes, perspectives, and/or skills
does the individual possess that would
benefit the workings of ACCV) and the
nominee’s field(s) of expertise; (2) the
name, address, daytime telephone
number, and email address at which the
nominator can be contacted; and (3) a
current copy of the nominee’s
curriculum vitae or resume. Nomination
packages may be submitted directly by
the individual being nominated or by
the person/organization recommending
the candidate. Nomination packages
will be collected and retained to create
a pool of possible future ACCV voting
members. When a vacancy occurs,
nomination packages from the
appropriate category will be reviewed
and nominees may be contacted at that
time.
HHS endeavors to ensure that the
membership of ACCV is balanced in
terms of points of view represented and
that individuals from a broad
representation of geographic areas,
gender, and ethnic and minority groups,
as well as individuals with disabilities,
are considered for membership.
Appointments shall be made without
discrimination on the basis of age,
disability, race, ethnicity, gender, sexual
orientation, national origin, or cultural,
religious, or socioeconomic status.
Individuals who are selected to be
considered for appointment will be
required to provide detailed information
regarding their financial holdings,
consultancies, and research grants or
contracts. Disclosure of this information
is required for HRSA ethics officials to
PO 00000
Frm 00031
Fmt 4703
Sfmt 4703
determine whether there is a potential
conflict of interest between the SGE’s
public duties as a member of ACCV and
their private interests, including an
appearance of a loss of impartiality as
defined by federal laws and regulations,
and to identify any required remedial
action needed to address the potential
conflict.
Authority: Under the authorities that
established the ACCV, the Federal
Advisory Committee Act of October 6,
1972, (Pub. L. 92–463, as amended) and
42 U.S.C. 300aa–19, section 2119 of the
Public Health Services (PHS) Act, HRSA
is requesting nominations for voting
members of ACCV.
Maria G. Button,
Director, Executive Secretariat.
[FR Doc. 2024–19808 Filed 9–3–24; 8:45 am]
BILLING CODE 4165–15–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Health Resources and Services
Administration
Meeting of the Advisory Committee on
Infant and Maternal Mortality
Health Resources and Services
Administration (HRSA), Department of
Health and Human Services (HHS).
ACTION: Notice.
AGENCY:
In accordance with the
Federal Advisory Committee Act, this
notice announces that the Advisory
Committee on Infant and Maternal
Mortality (ACIMM or Committee) has
scheduled a public meeting. Information
about ACIMM and the agenda for this
meeting can be found on the ACIMM
website at https://www.hrsa.gov/
advisory-committees/infant-mortality/
index.html.
DATES:
• October 16, 2024, from 9:30 a.m. to
5:15 p.m. Eastern Time; and
• October 17, 2024, from 9 a.m. to 1
p.m. Eastern Time.
ADDRESSES: This meeting will be held in
person at the Hubert H. Humphrey
Building, HHS Headquarters, 200
Independence Avenue SW, Conference
Room 505A, Washington, DC 20201,
and virtually via webinar. The webinar
link and log-in information will be
available at the ACIMM website before
the meeting at https://www.hrsa.gov/
advisory-committees/infant-mortality/
index.html.
FOR FURTHER INFORMATION CONTACT:
Vanessa Lee, MPH, Designated Federal
Official, Maternal and Child Health
Bureau, HRSA, 5600 Fishers Lane,
SUMMARY:
E:\FR\FM\04SEN1.SGM
04SEN1
ddrumheller on DSK120RN23PROD with NOTICES1
Federal Register / Vol. 89, No. 171 / Wednesday, September 4, 2024 / Notices
Rockville, Maryland 20857; 301–443–
0543; or SACIM@hrsa.gov.
SUPPLEMENTARY INFORMATION: ACIMM is
authorized by section 222 of the Public
Health Service Act (42 U.S.C. 217a), as
amended. The Committee is governed
by provisions of the Federal Advisory
Committee Act (5 U.S.C. chapter 10), as
amended.
ACIMM advises the Secretary of HHS
on department activities, partnerships,
policies, and programs directed at
reducing infant mortality, maternal
mortality and severe maternal
morbidity, and improving the health
status of infants and women before,
during, and after pregnancy. The
Committee provides advice on how to
coordinate federal, state, local, tribal,
and territorial governmental efforts
designed to improve infant mortality,
related adverse birth outcomes, and
maternal health, as well as influence
similar efforts in the private and
voluntary sectors. The Committee
provides guidance and
recommendations on the policies,
programs, and resources required to
address the disparities and inequities in
infant mortality, related adverse birth
outcomes and maternal health
outcomes, including maternal mortality
and severe maternal morbidity. With its
focus on underlying causes of the
disparities and inequities seen in birth
outcomes for women and infants, the
Committee advises the Secretary of HHS
on the health, social, economic, and
environmental factors contributing to
the inequities and proposes structural,
policy, and/or systems level changes.
The agenda for the October 16–17,
2024, meeting is being finalized and
may include the following topics:
federal updates; presentations and
Committee discussions on the
workgroup topics of rural health care
access, social drivers of health, and
women’s health before/between
pregnancies; and discussion of possible
recommendations to achieve optimal
maternal health and overall birth
outcomes for underserved populations,
including Black/African American
families. Agenda items are subject to
change as priorities dictate. Refer to the
ACIMM website listed above for any
updated information concerning the
meeting.
Members of the public will have the
opportunity to provide written or oral
comments. Public participants may
submit written statements in advance of
the scheduled meeting by emailing
SACIM@hrsa.gov. Oral comments will
be honored in the order they are
requested and may be limited as time
allows. Requests to submit a written
VerDate Sep<11>2014
21:26 Sep 03, 2024
Jkt 262001
statement or make oral comments to
ACIMM should be sent to Vanessa Lee,
Designated Federal Official, using the
email address above at least 3 business
days prior to the meeting.
Individuals who plan to attend and
need special assistance or another
reasonable accommodation should
notify Vanessa Lee at the contact
information listed above at least 10
business days prior to the meeting.
Since this meeting occurs in a federal
government building, attendees must go
through a security check to enter the
building. Non-U.S. Citizen attendees
must notify HRSA of their planned
attendance at least 20 business days
prior to the meeting to facilitate their
entry into the building. All attendees are
required to present government-issued
identification prior to entry.
Maria G. Button,
Director, Executive Secretariat.
[FR Doc. 2024–19741 Filed 9–3–24; 8:45 am]
71909
Kennedy Shriver National Institute of Child
Health and Human Development, NIH 6710B,
Rockledge Drive, Rm. 2131B, Bethesda, MD
20892, (301) 451–0000, jolanta.topczewska@
nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.864, Population Research;
93.865, Research for Mothers and Children;
93.929, Center for Medical Rehabilitation
Research; 93.209, Contraception and
Infertility Loan Repayment Program, National
Institutes of Health, HHS)
Dated: August 28, 2024.
Lauren A. Fleck,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2024–19747 Filed 9–3–24; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
BILLING CODE 4165–15–P
National Institute of General Medical
Sciences; Notice of Closed Meeting
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
National Institutes of Health
Eunice Kennedy Shriver National
Institute of Child Health & Human
Development; Notice of Closed
Meeting
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Eunice Kennedy
Shriver National Institute of Child Health and
Human Development Special Emphasis
Panel; Centers for Collaborative Research in
Fragile X and FMR1-Associated Conditions
(P50).
Date: November 20–21, 2024.
Time: 10:00 a.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Eunice Kennedy Shriver National
Institute of Child Health and Human
Development, 6710 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Jolanta Maria Topczewska,
Ph.D., Scientific Review Branch, Eunice
PO 00000
Frm 00032
Fmt 4703
Sfmt 4703
Name of Committee: National Institute of
General Medical Sciences Special Emphasis
Panel; Review of NIGMS National and
Regional Resources and Repositories Grant
Applications.
Date: October 30, 2024.
Time: 10:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
National Institute of General Medical
Sciences, Natcher Building, 45 Center Drive,
Bethesda, Maryland 20892 (Virtual Meeting).
Contact Person: Greg Bissonette, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, National Institute of General Medical
Sciences, National Institute of Health, 45
Center Drive, Room Hoteling, Bethesda,
Maryland 20892, 301–827–5118,
bissonettegb@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program No. 93.859, Biomedical Research
and Research Training, National Institutes of
Health, HHS)
E:\FR\FM\04SEN1.SGM
04SEN1
]]>Agencies
[Federal Register Volume 89, Number 171 (Wednesday, September 4, 2024)]
[Notices]
[Pages 71908-71909]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-19741]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Health Resources and Services Administration
Meeting of the Advisory Committee on Infant and Maternal
Mortality
AGENCY: Health Resources and Services Administration (HRSA), Department
of Health and Human Services (HHS).
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: In accordance with the Federal Advisory Committee Act, this
notice announces that the Advisory Committee on Infant and Maternal
Mortality (ACIMM or Committee) has scheduled a public meeting.
Information about ACIMM and the agenda for this meeting can be found on
the ACIMM website at https://www.hrsa.gov/advisory-committees/infant-mortality/.
DATES:
October 16, 2024, from 9:30 a.m. to 5:15 p.m. Eastern
Time; and
October 17, 2024, from 9 a.m. to 1 p.m. Eastern Time.
ADDRESSES: This meeting will be held in person at the Hubert H.
Humphrey Building, HHS Headquarters, 200 Independence Avenue SW,
Conference Room 505A, Washington, DC 20201, and virtually via webinar.
The webinar link and log-in information will be available at the ACIMM
website before the meeting at https://www.hrsa.gov/advisory-committees/infant-mortality/.
FOR FURTHER INFORMATION CONTACT: Vanessa Lee, MPH, Designated Federal
Official, Maternal and Child Health Bureau, HRSA, 5600 Fishers Lane,
[[Page 71909]]
Rockville, Maryland 20857; 301-443-0543; or [email protected].
SUPPLEMENTARY INFORMATION: ACIMM is authorized by section 222 of the
Public Health Service Act (42 U.S.C. 217a), as amended. The Committee
is governed by provisions of the Federal Advisory Committee Act (5
U.S.C. chapter 10), as amended.
ACIMM advises the Secretary of HHS on department activities,
partnerships, policies, and programs directed at reducing infant
mortality, maternal mortality and severe maternal morbidity, and
improving the health status of infants and women before, during, and
after pregnancy. The Committee provides advice on how to coordinate
federal, state, local, tribal, and territorial governmental efforts
designed to improve infant mortality, related adverse birth outcomes,
and maternal health, as well as influence similar efforts in the
private and voluntary sectors. The Committee provides guidance and
recommendations on the policies, programs, and resources required to
address the disparities and inequities in infant mortality, related
adverse birth outcomes and maternal health outcomes, including maternal
mortality and severe maternal morbidity. With its focus on underlying
causes of the disparities and inequities seen in birth outcomes for
women and infants, the Committee advises the Secretary of HHS on the
health, social, economic, and environmental factors contributing to the
inequities and proposes structural, policy, and/or systems level
changes.
The agenda for the October 16-17, 2024, meeting is being finalized
and may include the following topics: federal updates; presentations
and Committee discussions on the workgroup topics of rural health care
access, social drivers of health, and women's health before/between
pregnancies; and discussion of possible recommendations to achieve
optimal maternal health and overall birth outcomes for underserved
populations, including Black/African American families. Agenda items
are subject to change as priorities dictate. Refer to the ACIMM website
listed above for any updated information concerning the meeting.
Members of the public will have the opportunity to provide written
or oral comments. Public participants may submit written statements in
advance of the scheduled meeting by emailing [email protected]. Oral
comments will be honored in the order they are requested and may be
limited as time allows. Requests to submit a written statement or make
oral comments to ACIMM should be sent to Vanessa Lee, Designated
Federal Official, using the email address above at least 3 business
days prior to the meeting.
Individuals who plan to attend and need special assistance or
another reasonable accommodation should notify Vanessa Lee at the
contact information listed above at least 10 business days prior to the
meeting. Since this meeting occurs in a federal government building,
attendees must go through a security check to enter the building. Non-
U.S. Citizen attendees must notify HRSA of their planned attendance at
least 20 business days prior to the meeting to facilitate their entry
into the building. All attendees are required to present government-
issued identification prior to entry.
Maria G. Button,
Director, Executive Secretariat.
[FR Doc. 2024-19741 Filed 9-3-24; 8:45 am]
BILLING CODE 4165-15-P
